Radionuklidbehandling af neuroendokrine tumorer

Jann Mortensen; Peter Oturai; Liselotte Højgaard; Ulrich Knigge; Carsten Palnaes Hansen; Lars Martiný; Palle Rasmussen; Andreas Kjær; Peter Sandor Oturai

Radionuklidbehandling af neuroendokrine tumorer

Jann Mortensen, Peter Oturai, Liselotte Højgaard, Ulrich Knigge, Carsten Palnaes Hansen, Lars Martiný, Palle Rasmussen, Andreas Kjær, Peter Sandor Oturai

Abstract

Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with (177)Lu-DOTATATE treatment used at Rigshospitalet. Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.

Bidragets oversatte titel	[Radionuclide therapy for neuroendocrine tumours]
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	172
Udgave nummer	43
Sider (fra-til)	2950-3
Antal sider	4
ISSN	0041-5782
Status	Udgivet - 25 okt. 2010

Citationsformater

@article{3891d65ee9e241e7bcb6aa95f3e787dd,

title = "Radionuklidbehandling af neuroendokrine tumorer",

abstract = "Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with (177)Lu-DOTATATE treatment used at Rigshospitalet. Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.",

author = "Jann Mortensen and Peter Oturai and Liselotte H{\o}jgaard and Ulrich Knigge and Hansen, {Carsten Palnaes} and Lars Martin{\'y} and Palle Rasmussen and Andreas Kj{\ae}r and Oturai, {Peter Sandor}",

year = "2010",

month = oct,

day = "25",

language = "Dansk",

volume = "172",

pages = "2950--3",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "43",

}

TY - JOUR

T1 - Radionuklidbehandling af neuroendokrine tumorer

AU - Mortensen, Jann

AU - Oturai, Peter

AU - Højgaard, Liselotte

AU - Knigge, Ulrich

AU - Hansen, Carsten Palnaes

AU - Martiný, Lars

AU - Rasmussen, Palle

AU - Kjær, Andreas

AU - Oturai, Peter Sandor

PY - 2010/10/25

Y1 - 2010/10/25

N2 - Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with (177)Lu-DOTATATE treatment used at Rigshospitalet. Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.

AB - Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with (177)Lu-DOTATATE treatment used at Rigshospitalet. Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 172

SP - 2950

EP - 2953

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 43

ER -

Radionuklidbehandling af neuroendokrine tumorer

Abstract

Fingeraftryk

Citationsformater